Table 1.
List of albumin-based nanocarriers with nucleic acids for cancer therapy.
| Therapeutic Nucleic Acid | Type of Nanocarrier | Size (nm) | Z-Potential (mV) | Model System |
|---|---|---|---|---|
| Plasmid | ||||
| Plasmid pORF-hTRAIL (pDNA) |
BSA NPs | 115.7 | −15.4 (pH 7) +11.3 (pH 2) |
BALB/c mice bearing i.c. C6 gliomas (Brain Tumor [23]) |
| Plasmid pCMV-EGFP-C | PEI Polyplex | 140–450 | NA | HeLa cells [44] |
| hMDA-7 plasmid | BSA NPs | 115.6 | +33.8 | PANC-1 and BXPC-3 human pancreatic cell lines and tumor-induced BALB/c nude mice [24] |
| pGL3 vector coding for the firefly luciferase gene | HSA-PEI NPs | 300 to 700 | −7 in H2O +16 in 1 mM KCl |
Human epithelial kidney 293-cells [45] |
| Oligonucleotides | ||||
| Oligonucleotide | Nanoconjugate | 13 | NA | Tumor spheroids of A375/GFP cells [46] |
| Antisense Oligonucleotides (ASOs) | HSA NPs | 290–330 | NA | MCF-7 cells [47] |
| Akt1 ASOs | Lipid-HSA NPs | 108.6 | 10.5 | KB cells and A549 cells [48] |
| siRNAs | ||||
| VEGF siRNA | Self-crosslinked HSA NPs | 169.3 | NA | B16F10 murine melanoma cells, squamous cell carcinoma cells (SCC7), and human prostatic carcinoma cells (PC-3) [49] |
| Bcl-2-specific siRNA | Anti-ErbB-2 antibody conjugated BSA nanocomplex | 278 | −39.6 | SK-BR-3 and MCF-7 breast cancer cells [50] |
| phrGFP-targeted siRNA | HSA-coated lipid NPs | 79.5 | +15.3 | MCF-7, MDA-MB-231, SK-BR-3 cells, and phrGFP-transfected MCF-7 xenograft tumor mice model [51] |
| Immunotherapeutic biologics | ||||
| Vaccine conjugated with Evans blue (EB) and CpG | Albumin/vaccine nanocomplexes | ~13 | NA | Female C57BL/6 mice s.c. inoculated with EL4 cells, or EG7.OVA cells, B16F10 cells, MC38 cells on the shoulder [52] |
| PD-L1 plasmid (CRISPR/Cas9) | Stearyl PEI complexed HSA NPs | 203 | 13 | Mouse colon carcinoma CT26 cells [53] |
BSA NPs = Bovine Serum Albumin Nanoparticles; HAS = Human Serum Albumin; VEGF = Vascular Endothelial Growth Factor; CRISPR = Clustered, Regularly Interspaced, Short Palindromic Repeat.